The objective of our study was to determine the spectral characteristic of vedolizumab-treated IBD patient’s macromolecular assemblies of peripheral blood cells and of the specific spectra with PIMS and NPOT to enable stratification of anti-TNF refractory IBD patients into responders or nonresponders to subsequent vedolizumab therapy. The gene discussed is TNF; the disease is inflammatory bowel disease.